Reformulation of Current Recommendations for Target Serum Lithium Concentration According to Clinical Indication, Age and Physical Comorbidity
- 1 December 2011
- journal article
- review article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 45 (12) , 1026-1032
Abstract
Background: There have been significant changes in the nature of psychiatric patient populations and patterns of drug prescribing in mood disorders since serum lithium monitoring was introduced. It seems opportune to review current guidelines for target lithium concentration given the decline in lithium monotherapy and increase in the numbers of older people and those with comorbid physical disease administered lithium. Method: A review was made of the literature of lithium monitoring and target serum concentration in mood disorders, older people, and comorbid physical illness. Results: Current guidelines, which generally recommend a target serum concentration of 0.5/0.6 to 1.1/1.2 mmol/L, have a number of limitations. A target lithium level of > 0.8 mmol/L is inappropriate given poor tolerability, and adequate efficacy when combination lithium-antipsychotic therapy is used at this or lower levels. Guidelines have largely failed to match specific clinical indications to serum levels, and to consider comorbid physical illness factors known to be associated with lithium toxicity. Conclusion: For most patients, a target serum lithium concentration range of 0.5–0.8 mmol/L, varying according to clinical indication, age and concurrent physical status, seems most appropriate in enhancing efficacy and minimizing adverse effects. The lower end of this range (0.5–0.6 mmol/L) is recommended for patients 50 years and over; those with diabetes insipidus, renal impairment or thyroid dysfunction; those administered diuretics, angiotensin converting enzyme (ACE) inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs)/COX-2 inhibitors; and in the prophylaxis of bipolar depression and management of acute unipolar depression. The higher end of this range (0.7–0.8 mmol/L) is recommended in the management of acute mania and prophylaxis of mania.Keywords
This publication has 40 references indexed in Scilit:
- Optimal Frequency of Lithium Administration in the Treatment of Bipolar DisorderCNS Drugs, 2011
- Rapid Onset of Neurological Symptoms and Lithium Toxicity on Starting MeloxicamAustralian & New Zealand Journal of Psychiatry, 2010
- Is Lithium in a Class of Its Own? A Brief Profile of Its Clinical UseAustralian & New Zealand Journal of Psychiatry, 2009
- Adjunctive treatment of acute mania: a clinical overviewActa Psychiatrica Scandinavica, 2007
- Lithium in the Prevention of Suicidal Behavior and All-Cause Mortality in Patients With Mood Disorders: A Systematic Review of Randomized TrialsAmerican Journal of Psychiatry, 2005
- What Is a “Mood Stabilizer”? An Evidence-Based ResponseAmerican Journal of Psychiatry, 2004
- Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidenceBMJ, 2003
- Therapeutic drug monitoring of psychotropic medicationsBritish Journal of Clinical Pharmacology, 2001
- Longitudinal Studies on the Rate of Decline in Renal Function with AgeJournal of the American Geriatrics Society, 1985
- Serum Level Monitoring and Clinical Pharmacokinetics of LithiumClinical Pharmacokinetics, 1977